GlaxoSmithKline will transfer to Cytokinetics all rights to GSK-923295, a drug candidate for solid tumors, by the end of February after the two drugmakers agreed to terminate their eight-year research partnership. Cytokinetics said it plans to license GSK-923295 as well as SB-743921 and SB-715992, two other cancer drug candidates that GSK turned over in 2008.

Related Summaries